205 related articles for article (PubMed ID: 25902842)
41. [Early response to idursulfase in a 31-year old male patient with Hunter syndrome].
Pérez-Calvo J; Bergua Sanclemente I; López Moreno MJ; Torralba Cabeza MÁ; Amores Arriaga B
Rev Clin Esp; 2011; 211(7):e42-5. PubMed ID: 21524741
[TBL] [Abstract][Full Text] [Related]
42. [Idursulfase desensitization in a child with Hunter syndrome (mucopolysaccharidosis II)].
Bustamante LL; Garavaglia L; Garramone EI; Amartino H; Parisi CA
Arch Argent Pediatr; 2021 Feb; 119(1):e41-e44. PubMed ID: 33458989
[TBL] [Abstract][Full Text] [Related]
43. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
Whiteman DA; Kimura A
Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administration.
Xie H; Chung JK; Mascelli MA; McCauley TG
PLoS One; 2015; 10(4):e0122453. PubMed ID: 25836678
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of Idursulfase therapy in patients with Mucopolysaccharidosis type II who initiated enzyme replacement therapy in adult age. A systematic review of the literature.
Pérez-López J; Moltó-Abad M; Muñoz-Delgado C; Morales-Conejo M; Ceberio-Hualde L; Del Toro M
Mol Genet Metab; 2018 Jul; 124(3):216-227. PubMed ID: 29801985
[TBL] [Abstract][Full Text] [Related]
46. [Efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II with and without comparison to placebo: systematic review and meta-analysis].
Alegra T; Eizerik DP; de Cerqueira CC; Pereira TV; Dornelles AD; Schwartz IV
Cad Saude Publica; 2013 Nov; 29 Suppl 1():S45-58. PubMed ID: 25402250
[TBL] [Abstract][Full Text] [Related]
47. Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study.
Guffon N; Heron B; Chabrol B; Feillet F; Montauban V; Valayannopoulos V
Orphanet J Rare Dis; 2015 Apr; 10():43. PubMed ID: 25887606
[TBL] [Abstract][Full Text] [Related]
48. Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up.
Tylki-Szymanska A; Jurecka A; Zuber Z; Rozdzynska A; Marucha J; Czartoryska B
Acta Paediatr; 2012 Jan; 101(1):e42-7. PubMed ID: 21672014
[TBL] [Abstract][Full Text] [Related]
49. Comparative study of idursulfase beta and idursulfase in vitro and in vivo.
Kim C; Seo J; Chung Y; Ji HJ; Lee J; Sohn J; Lee B; Jo EC
J Hum Genet; 2017 Feb; 62(2):167-174. PubMed ID: 27829684
[TBL] [Abstract][Full Text] [Related]
50. Clinical response to long term enzyme replacement treatment in children, adolescent and adult patients with Hunter syndrome.
Dalmau Serra J; Vitoria Miñana I; Calderón Fernández R; Cortell Aznar I
Med Clin (Barc); 2015 Nov; 145(9):392-8. PubMed ID: 26360015
[TBL] [Abstract][Full Text] [Related]
51. Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years.
Tomanin R; Zanetti A; D'Avanzo F; Rampazzo A; Gasparotto N; Parini R; Pascarella A; Concolino D; Procopio E; Fiumara A; Borgo A; Frigo AC; Scarpa M
Orphanet J Rare Dis; 2014 Sep; 9():129. PubMed ID: 25231261
[TBL] [Abstract][Full Text] [Related]
52. Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase 2/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis II.
Yee KS; Lewis S; Evans E; Romano C; Alexanderian D
Orphanet J Rare Dis; 2024 Mar; 19(1):110. PubMed ID: 38462612
[TBL] [Abstract][Full Text] [Related]
53. Idursulfase for the treatment of mucopolysaccharidosis II.
Clarke LA
Expert Opin Pharmacother; 2008 Feb; 9(2):311-7. PubMed ID: 18201153
[TBL] [Abstract][Full Text] [Related]
54. Home treatment in paediatric patients with Hunter syndrome: the first Italian experience.
Ceravolo F; Mascaro I; Sestito S; Pascale E; Lauricella A; Dizione E; Concolino D
Ital J Pediatr; 2013 Sep; 39():53. PubMed ID: 24011228
[TBL] [Abstract][Full Text] [Related]
55. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
Wraith JE
Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193
[TBL] [Abstract][Full Text] [Related]
56. Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points.
Glamuzina E; Fettes E; Bainbridge K; Crook V; Finnegan N; Abulhoul L; Vellodi A
J Inherit Metab Dis; 2011 Jun; 34(3):749-54. PubMed ID: 21327479
[TBL] [Abstract][Full Text] [Related]
57. Effects of idursulfase enzyme replacement therapy for Mucopolysaccharidosis type II when started in early infancy: comparison in two siblings.
Tajima G; Sakura N; Kosuga M; Okuyama T; Kobayashi M
Mol Genet Metab; 2013 Mar; 108(3):172-7. PubMed ID: 23375472
[TBL] [Abstract][Full Text] [Related]
58. Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS).
Spataro F; Viggiani F; Macchia DG; Rollo V; Tummolo A; Suppressa P; Sabba' C; Rossi MP; Giliberti L; Satriano F; Nettis E; Di Bona D; Caiaffa MF; Fischetto R; Macchia L
Orphanet J Rare Dis; 2022 Nov; 17(1):402. PubMed ID: 36329518
[TBL] [Abstract][Full Text] [Related]
59. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.
Garcia AR; DaCosta JM; Pan J; Muenzer J; Lamsa JC
Mol Genet Metab; 2007 Jun; 91(2):183-90. PubMed ID: 17459751
[TBL] [Abstract][Full Text] [Related]
60. Intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II: Final report of 5-year results from a Japanese open-label phase 1/2 study.
Seo JH; Kosuga M; Hamazaki T; Shintaku H; Okuyama T
Mol Genet Metab; 2023 Dec; 140(4):107709. PubMed ID: 37922836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
